See the latest news and media coverage for ExpreS2ion. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage immunotherapy biotechnology company
expres2ionbio.comLast updated
In short: ExpreS2ion reported positive Phase I data for its breast cancer vaccine and raised significant capital via rights issues and warrants.
The company raised SEK 32.4 million via rights issue, achieving SEK 34.4 million cash. Early ES2B-C001 data shows strong antibody responses, while pipeline partners advance.
DSMB recommended expanding the 450 μg cohort; antibody responses were seen in 12 of 13 evaluable patients. Phase II initiation is now targeted for H2 2027.
The offering aims to raise capital for development and expansion activities.
The application covers recombinant production with xylosylated N-glycans and includes immunogenicity data.
Risk warning: Trading in financial instruments and/or cryptocurrencies is associated with a high risk, such as the chance that you will lose all or part of the...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least...
Hørsholm, Denmark, 12 August 2026 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a pipeline of novel ...
ExpreS2ion Biotechnologies reported a 36% year-over-year increase in total income for the third quarter of 2025. The company also...
Track ExpreS2ion and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to ExpreS2ion and other trending companies.